FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996306051> ?p ?o ?g. }

• W1996306051 endingPage "1720" @default.
• W1996306051 startingPage "1720" @default.
• W1996306051 abstract "On the basis of human epidermal growth factor receptor 2 (HER-2) status, patients with breast cancer are classified as having HER-2-negative or HER-2-positive disease. Prognosis of HER-2-positive, as compared to HER-2negative, disease is poorer. But by adding HER-2 signaling pathway inhibitors, including trastuzumab, to standard chemotherapy, we can change this poor outcome. Given that more than three of four patients diagnosed with breast cancer have a HER-2-negative disease and yet in the absence of any deregulated signaling pathway having been discovered no targeted therapy can be applied, there is major interest in how best treat these patients. Several phase II and III randomized trials are underway to test many combinations of targeted agents. But the expectations are limited by the lack of the identification regarding which signaling pathways are activated in these HER-2-negative patients. Therefore, translational research on HER-2-negative disease is currently attracting major interest. Mizell and colleagues evaluated whether chemokine receptor CXCR4 expression could be used as a prognostic factor. In their report in a recent issue of the Annals of Surgical Oncology, the authors analyzed CXCR4 levels from primary tumors of 115 HER-2-negative breast cancer patients with stage I to III disease. The authors report that overall survival and disease-free survival were far lower among 13 patients with CXCR4 overexpression than among 102 patients with low CXCR4 expression in primary tumors. The authors propose the performance of either a prospective clinical trial and/or an external validation study to validate the prognostic significance of.CXCR4 expression. But the study is limited by the very small number of patients (n = 13) with CXCR4 overexpression. Comparative effectiveness research requires much larger samples than 12 cases, particularly when Kaplan-Meier survival curves and Cox proportional hazard ratio models are used for comparisons. Such comparisons need comparability of the two groups at baseline, including tumor stage, clinicopathologic factors, and treatment. Currently, treatment of patients with HER-2-negative tumor is suboptimal. Given the high complexity and erogeneity of the breast, conventional single-protein-coding gene research has many limitations. There is a need to identify which other signaling pathways, beyond those in the epidermal growth factor receptor family (HER-1, HER2, HER-3, HER-4)—for example, Wnt/Notch—are activated and predict how their interactions in HER-2-negative disease affect outcome. This intracellular signaling pathways network understanding appears may now become feasible with the advent of next-generation DNA sequencing technology. These technological advances, including genomewide RNA, serial analysis of gene expression (SAGE), micro-RNAs, protein-DNA interactions, and comprehensive analyses of transcriptomes and interactomes, open new roads for the development of new markers and drugs against breast cancer and other solid tumors." @default.
• W1996306051 created "2016-06-24" @default.
• W1996306051 creator A5043933390 @default.
• W1996306051 creator A5046204234 @default.
• W1996306051 creator A5073133050 @default.
• W1996306051 creator A5078943260 @default.
• W1996306051 date "2010-03-03" @default.
• W1996306051 modified "2023-09-25" @default.
• W1996306051 title "HER-2-Negative Breast Cancer Limitations and Next-Generation Sequencing Technology Promises" @default.
• W1996306051 cites W1997894191 @default.
• W1996306051 cites W2047031939 @default.
• W1996306051 cites W2071508515 @default.
• W1996306051 cites W4238448376 @default.
• W1996306051 doi "https://doi.org/10.1245/s10434-010-0973-8" @default.
• W1996306051 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20198443" @default.
• W1996306051 hasPublicationYear "2010" @default.
• W1996306051 type Work @default.
• W1996306051 sameAs 1996306051 @default.
• W1996306051 citedByCount "2" @default.
• W1996306051 crossrefType "journal-article" @default.
• W1996306051 hasAuthorship W1996306051A5043933390 @default.
• W1996306051 hasAuthorship W1996306051A5046204234 @default.
• W1996306051 hasAuthorship W1996306051A5073133050 @default.
• W1996306051 hasAuthorship W1996306051A5078943260 @default.
• W1996306051 hasBestOaLocation W19963060511 @default.
• W1996306051 hasConcept C121608353 @default.
• W1996306051 hasConcept C126322002 @default.
• W1996306051 hasConcept C143998085 @default.
• W1996306051 hasConcept C2780140570 @default.
• W1996306051 hasConcept C530470458 @default.
• W1996306051 hasConcept C71924100 @default.
• W1996306051 hasConceptScore W1996306051C121608353 @default.
• W1996306051 hasConceptScore W1996306051C126322002 @default.
• W1996306051 hasConceptScore W1996306051C143998085 @default.
• W1996306051 hasConceptScore W1996306051C2780140570 @default.
• W1996306051 hasConceptScore W1996306051C530470458 @default.
• W1996306051 hasConceptScore W1996306051C71924100 @default.
• W1996306051 hasIssue "6" @default.
• W1996306051 hasLocation W19963060511 @default.
• W1996306051 hasLocation W19963060512 @default.
• W1996306051 hasOpenAccess W1996306051 @default.
• W1996306051 hasPrimaryLocation W19963060511 @default.
• W1996306051 hasRelatedWork W1484755419 @default.
• W1996306051 hasRelatedWork W1504984147 @default.
• W1996306051 hasRelatedWork W2013809648 @default.
• W1996306051 hasRelatedWork W2121904146 @default.
• W1996306051 hasRelatedWork W2123174954 @default.
• W1996306051 hasRelatedWork W2224319365 @default.
• W1996306051 hasRelatedWork W2503964141 @default.
• W1996306051 hasRelatedWork W3193380953 @default.
• W1996306051 hasRelatedWork W4248497383 @default.
• W1996306051 hasRelatedWork W3113313363 @default.
• W1996306051 hasVolume "17" @default.
• W1996306051 isParatext "false" @default.
• W1996306051 isRetracted "false" @default.
• W1996306051 magId "1996306051" @default.
• W1996306051 workType "article" @default.